Novartis AG Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets
Novartis AG (NVS) reported Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets of $1.10 billion for the 12-month period ending 2025-12-31, per its 20-F filed 2026-02-04.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets · last filed 2026-02-04
| Period end | Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets 12 month |
|---|---|
| 2025-12-31 | $1.10B 20-F · filed 2026-02-04 |
| 2024-12-31 | $1.04B 20-F · filed 2026-02-04 |
| 2023-12-31 | $865.00M 20-F · filed 2026-02-04 |